BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 8866387)

  • 1. Predictors of persistent disease in women with complete hydatidiform mole.
    Ayhan A; Tuncer ZS; Halilzade H; Küçükali T
    J Reprod Med; 1996 Aug; 41(8):591-4. PubMed ID: 8866387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Persistent trophoblast disease following partial molar pregnancy.
    Wielsma S; Kerkmeijer L; Bekkers R; Pyman J; Tan J; Quinn M
    Aust N Z J Obstet Gynaecol; 2006 Apr; 46(2):119-23. PubMed ID: 16638033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of low risk of persistent trophoblastic disease in molar pregnancies.
    Niemann I; Petersen LK; Hansen ES; Sunde L
    Obstet Gynecol; 2006 May; 107(5):1006-11. PubMed ID: 16648403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recurrent gestational trophoblastic disease after hCG normalization following hydatidiform mole in The Netherlands.
    Kerkmeijer LG; Wielsma S; Massuger LF; Sweep FC; Thomas CM
    Gynecol Oncol; 2007 Jul; 106(1):142-6. PubMed ID: 17462723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pre-evacuation hCG glycoforms in uneventful complete hydatidiform mole and persistent trophoblastic disease.
    Thomas CM; Kerkmeijer LG; Ariaens HJ; van der Steen RC; Massuger LF; Sweep FC
    Gynecol Oncol; 2010 Apr; 117(1):47-52. PubMed ID: 20116088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of risk factors for persistent gestational trophoblastic disease.
    Khoo SK; Baartz D; Sidhu M; Yip WL; Tripcony L
    Aust N Z J Obstet Gynaecol; 2009 Dec; 49(6):657-9. PubMed ID: 20070718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of recurrent hydatidiform mole and subsequent pregnancy outcome following complete or partial hydatidiform molar pregnancy.
    Sebire NJ; Fisher RA; Foskett M; Rees H; Seckl MJ; Newlands ES
    BJOG; 2003 Jan; 110(1):22-6. PubMed ID: 12504931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measurement of CA-125 in trophoblastic disease.
    Kohorn EI
    Gynecol Oncol; 2000 Jul; 78(1):39-42. PubMed ID: 10873407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low risk of relapse after achieving undetectable HCG levels in women with partial molar pregnancy.
    Wolfberg AJ; Growdon WB; Feltmate CM; Goldstein DP; Genest DR; Chinchilla ME; Berkowitz RS; Lieberman ES
    Obstet Gynecol; 2006 Aug; 108(2):393-6. PubMed ID: 16880311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low risk of relapse after achieving undetectable HCG levels in women with complete molar pregnancy.
    Wolfberg AJ; Feltmate C; Goldstein DP; Berkowitz RS; Lieberman E
    Obstet Gynecol; 2004 Sep; 104(3):551-4. PubMed ID: 15339768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The natural history of theca lutein cysts.
    Montz FJ; Schlaerth JB; Morrow CP
    Obstet Gynecol; 1988 Aug; 72(2):247-51. PubMed ID: 2455880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Guidelines following hydatidiform mole: a reappraisal.
    Kerkmeijer L; Wielsma S; Bekkers R; Pyman J; Tan J; Quinn M
    Aust N Z J Obstet Gynaecol; 2006 Apr; 46(2):112-8. PubMed ID: 16638032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Analysis of prophylactic chemotherapy outcome and clinical characteristics in patients of high-risk hydatidiform mole].
    Geng S; Feng FZ; Xiang Y; Wan XR; Zhou Y
    Zhonghua Fu Chan Ke Za Zhi; 2011 Jan; 46(1):24-7. PubMed ID: 21429430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The risk factors in the development of persistent trophoblastic disease following hydatidiform mole.
    Tangtrakul S; Srisupundit S; Linasmita V; Bullangpoti S; Bhamarapravati Y
    J Med Assoc Thai; 1990 Feb; 73 Suppl 1():33-6. PubMed ID: 2161897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Persistent gestational trophoblastic neoplasia after partial hydatidiform mole incidence and outcome.
    Hancock BW; Nazir K; Everard JE
    J Reprod Med; 2006 Oct; 51(10):764-6. PubMed ID: 17086803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathologic features of sharp curettings in complete hydatidiform mole. Predictors of persistent gestational trophoblastic disease.
    Rice LW; Genest DR; Berkowitz RS; Goldstein DP; Bernstein MR; Redline RW
    J Reprod Med; 1991 Jan; 36(1):17-20. PubMed ID: 1848894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The risk of persistent trophoblastic disease after hydatidiform mole classified by morphology and ploidy.
    Niemann I; Hansen ES; Sunde L
    Gynecol Oncol; 2007 Feb; 104(2):411-5. PubMed ID: 17011616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma human chorionic gonadotropin disappearance in hydatidiform mole: a central registry report from the Netherlands.
    Franke HR; Risse EK; Kenemans P; Houx PC; Stolk JG; Vooijs GP
    Obstet Gynecol; 1983 Oct; 62(4):467-73. PubMed ID: 6888825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Duration of human chorionic gonadotropin surveillance for partial hydatidiform moles.
    Lavie I; Rao GG; Castrillon DH; Miller DS; Schorge JO
    Am J Obstet Gynecol; 2005 May; 192(5):1362-4. PubMed ID: 15902109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Persistence of gestational trophoblastic disease for longer than 1 year following evacuation of hydatidiform mole.
    Elmer DB; Granai CO; Ball HG; Curry SL
    Obstet Gynecol; 1993 May; 81(5 ( Pt 2)):888-90. PubMed ID: 7682320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.